brecon_kay_ohagan

Boehringer’s Kay O’Hagan moves to Brecon

pharmafile | March 2, 2011 | Appointment | Manufacturing and Production, Research and Development Brecon, Kay O'Hagan, appointment, manufacturing and production, research and development 

Kay O’Hagan has joined commercial packaging and clinical trials supply services company Brecon Pharmaceuticals as director of quality assurance and regulatory affairs.

She is a microbiologist by training and was formerly head of quality assurance for Boehringer Ingelheim in the UK.

“In my most recent position I was involved in our supplier audit of Brecon and the results were impressive,” she said. “The relationship was very positive and I was aware that Brecon has a good reputation in the industry. When I visited the company’s site in Hay-on-Wye, I was impressed by Brecon’s people-based, quality-focused approach, and I am therefore very happy to be joining the team at this stage in the company’s development.”

Advertisement

Kay – a Qualified Person (QP) – will assume full responsibility for Brecon’s quality assurance and regulatory activities, and will head up the company’s team of Qualified Persons.

“QPs are in great demand in the industry and I am delighted to be given the opportunity to work with the four QPs at Brecon on the complex task of releasing various companies’ products into the current market. It will be a challenge – but one I am really looking forward to,” she said.

Kay’s 30-year career in the industry includes a seven-year stint with Boehringer and four years with Novartis UK as quality assurance manager.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

Rotzinger launches modular filling and capping platform for over-the-counter products

Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

The Gateway to Local Adoption Series

Latest content